WMT COMPOSITE DBM

{0}------------------------------------------------ KOR3270 # 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS AUG 2 7 2009 In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807, this information serves as a Summary of Safety and Effectiveness for the use of WMT Composite DBM. Submitted By: Date: Contact Person: Proprietary Name: Common Name: Classification Name and Reference: Wright Medical Technology, Inc. September 24, 2008 Ryan M. Belaney Sr. Regulatory Affairs Specialist/Product Development Engineer (as of 2/10/09) WMT Composite DBM Bone Void Filler Orthopedic/87/MOV 21 CFR 888.3045 - Resorbable Calcium Salt Bone Void Filler Device - Class II Device Product Code and Panel Code: #### DEVICE INFORMATION #### A. INTENDED USE WMT Composite DBM resultant paste is intended for use as a bone graft substitute to be injected or digitally packed into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremities and pelvis) to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The paste provides a bone graft substitute that resorbs and is replaced with bone during the healing process. The WMT Composite DBM paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process. The WMT Composite DBM Core Decompression Procedure Kit, consisting of a bone void filler and manual surgical instruments, is intended to be used during core decompression procedures. The bone void filler component resorbs and is replaced by bone during the healing process. The bone void filler included in the WMT Composite DBM Core Decompression Kit is not intended to be used as a load bearing device. WMT Composite DBM is provided sterile for single use. ## B. DEVICE DESCRIPTION The design features of the WMT Composite DBM Kit are substantially equivalent to the design features of the predicate devices. A brief description of the WMT Composite DBM implant and a summary of additional performance/marketing claims are provided below. {1}------------------------------------------------ ### IMPLANT DESCRIPTION WMT Composite DBM consists of a calcium sulfate, calcium phosphate, and demineralized bone matrix bone void filler consisting of a powder component and an aqueous mixing solution. When the two components are mixed, according to directions, an injectable paste is formed which subsequently hardens via hydration reactions. ## NON-CLINICAL PERFORMANCE/MARKETING CLAIMS Accelerated healing compared to PRO-DENSE®*: At 6 weeks, the percentage of new bone formation within the WMT Composite DBM defects was approximately the same as for PRO-DENSE® treated defects although there was less residual material in the WMT Composite DBM defects at this time point compared to PRO-DENSE®. Compared to PRO-DENSE®, WMT Composite DBM showed accelerated and more complete healing as evidenced by new bone formation across the width of the defect. Accelerated healing compared to autograft*: Compared to autograft and normal bone, WMT Composite DBM showed accelerated new bone formation at 13 and 26 weeks. This was evident by the slightly higher stiffness, the greater amount of newly formed bone, and statistically significantly greater compressive strength shown for WMT Composite DBM. By comparing the 26-week clinical and contact radiographs and gross cross-sectional images and histological images, there appeared to be little to no apparent differences between defects filled with either WMT Composite DBM or autograft. Comparison of percentage of new bone, compressive strength, and modulus of elasticity showed no statistically significant differences between the materials at 26 weeks. Bone remodeling to normal bone at 13 weeks *: From 6 to 13 weeks, the amount of new bone formation in the WMT Composite DBM defects increased. At 13 weeks, the WMT Composite DBM material had substantially remodeled compared to the 6-week time point. From 13 to 26 weeks, the amount of new bone formation for WMT Composite DBM was sustained and the amount of residual material continued to decrease. Further, at every time point, a comparison of WMT Composite DBM to normal bone shows no significant differences for percentage new bone, compressive strength, and modulus of elasticity. Following the same test design as the predicate, ALLOMATRIX®, the osteoinductive property of WMT Composite DBM was confirmed. * All claims are based on a critically sized canine proximal humerus defect model. It is unknown how results from the canine model compare with clinical results in humans. ## C. SUBSTANTIAL EQUIVALENCE INFORMATION The intended use, type of interface, operating principles, shelf life, and design features of the WMT Composite DBM are substantially equivalent to the previously cleared predicates. Additionally, the safety and effectiveness of the WMT Composite DBM is adequately supported by the substantial equivalent information, materials data, and testing results provided within this Premarket Notification. {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services - USA. The seal features an eagle with three lines representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. The seal is black and white. Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002 AUG 2 7 2009 Wright Medical Technology, Inc. % Mr. Ryan Belaney Sr. Regulatory Affairs Specialist 5677 Airline Road Arlington, Tennessee 38002 Re: K083270 Trade Name: WMT Composite DBM Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: II Product Code: MOV, MBP Dated: August 3, 2009 Received: August 11, 2009 Dear Mr. Belaney: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilsting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {3}------------------------------------------------ Page 2 - Mr. Ryan Belaney forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours. Houbare Bruckner Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use Statement 510(k) Number: K083270 Device Name: WMT Composite DBM Indications For Use: WMT Composite DBM resultant paste is intended for use as a bone graft substitute to be injected or digitally packed into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremities and pelvis) to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The paste provides a bone graft substitute that resorbs and is replaced with bone during the healing process. The WMT Composite DBM paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process. The WMT Composite DBM Core Decompression Procedure Kit, consisting of a bone void filler and manual surgical instruments, is intended to be used during core decompression procedures. The bone void filler component resorbs and is replaced by bone during the healing process. The bone void filler included in the WMT Composite DBM Core Decompression Kit is not intended to be used as a load bearing device. WMT Composite DBM is provided sterile for single use only. Henneth C. Fager (Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K083270 Prescription Use ブ (Per21 CFR 801.109) OR (Division Sign-Off) Division of General Restorative Devices 510(k) Number Over-The Counter Use (Optional Format 1-2-96) ### (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)